Kite Pharma Announces Worldwide Biopharma Facility in the Netherlands

The biopharma company will advance production of cancer cell therapies in Europe

biopharma

California-based biopharmaceutical company Kite Pharma, a Gilead company, announced the opening of a new facility in the Netherlands to advance production of its cancer cell therapies. The 117,000-square-foot site is located at the SEGRO Park Amsterdam Airport in Hoofddorp. Kite’s new facility will enable the company to more efficiently engineer and deliver its cell therapies to cancer patients in Europe.

“We are pleased to be leading a new frontier of cancer innovation that is bringing hope for people living with cancer,” commented John F. Milligan, PhD, Gilead’s President and Chief Executive Officer. “This new European manufacturing facility will enable personalized cell therapies to be manufactured in closer geographic proximity to the patients who will receive them, potentially shortening the turnaround time for people who urgently need care.”

In addition to existing therapies, Kite Pharma’s new facility in Holland will produce innovative new cell therapies. And, an expected 300 new jobs will be created by 2020.

Holland’s Strength in Biopharmaceuticals

The Netherlands is a European leader in life sciences and biopharma innovation. The country’s world-class research institutes are a top reason why biopharma companies choose Holland. The Netherlands offers high-quality infrastructure for pharmaceutical data and analysis thanks to its very well-documented population. It is home to the Medicines Evaluation Board (MEB), one of the top European regulators for central and pharmacovigilance procedures. Additionally, Holland will become the EU regulatory base for all human and veterinary medicines when the European Medicines Agency (EMA) relocates to Amsterdam next spring.

Kite Pharma’s expansion in the Netherlands builds upon the company’s European headquarters, already in Amsterdam. Kite also collaborates with the Netherlands Cancer Institute (NKI).

Source: Kite Pharma

15 May 2018
Life Sciences & Health Learn more

Get In Touch

Contact us
This website uses cookies for necessary website functionalities, analytics & marketing. Click on Cookie Settings if you wish to change these settings. More information on our cookie policy can be found in our Privacy Policy notice.
Privacy Policy
Cookie Settings
Accept Cookies

Cookie Settings

You can access these settings at any time by selecting the Cookies link in the footer of this website.

Privacy Policy
Privacy Policy
Strictly Necessary Cookies

These cookies are needed for our website to function providing security and other essentials. Therefore they are always on but they do not contain personally identifiable information (PII). The website cannot function properly without these cookies.

Name Purpose
Cookie Settings If you've set preferences (which cookies you accept and which you don't) we store your preferences here to make sure we don't load anything that you didn't agree to.
WordPress Cookies WordPress sets a couple of cookies that track logged in users and store user preferences set in their WordPress user profile. These are set for members of the NFIA website only - members of our staff.
PHP Session Cookies These allow us to remember the layout and filtering content preferences made for the duration of the user's session. We have made sure no personally identifiable information (PII) is recorded.
SPAM Protection Cookies These allow us to protect our contact and newsletter forms from SPAM bots. We have made sure no personally identifiable information (PII) is recorded. Uses Google reCaptcha V3.
Read More +
Analytics Cookies

Analytics cookies allow us to gather data to help us better understand our visitors and offer them a better experience.

Off
Name Purpose
Google Analytics Analytics help us deliver better content to our audience. We have made sure no personally identifiable information (PII) is sent by anonymizing IPs.
Read More +
Marketing Cookies

Marketing cookies allow us to link up our social media activities on various channels such as LinkedIn and Twitter. These cookies are not used for remarketing purposes.

Off
Name Purpose
KickFire Analytics IP Address Recognition Tool that Identifies companies and visitors to the site, as well as integrate account data into Analytics.
Twitter InSights IP Address Recognition Tool that allows us to match visitors to companies for marketing purposes.
Adwords Remarketing Enables creation of remarketing lists on Google Ads.
LinkedIn InSights Enables audience list building and conversion tracking on LinkedIn.
Read More +
Save